Alemtuzumab Multiple Sclerosis Therapy Can Cause Severe Side Effects

The multiple sclerosis (MS) medication alemtuzumab can provoke severe and unpredictable side effects, scientists report. Multiple sclerosis is the most common neurological condition in young adults. It is characterised by chronic inflammation in the central nervous system.

The paper, by a team led by Dr Aiden Haghikia and Dr Ralf Gold from the Department of Neurology of the Ruhr-Universität Bochum at St. Josef’s Hospital, reports on two patients for whom the infusion of alemtuzumab significantly worsened symptoms.

The team also describe a treatment that successfully lessened the unwanted side effects.

“This therapeutic algorithm could help MS patients around the world who develop similar side effects under alemtuzumab,” says Haghikia.

Alemtuzumab Therapy

Alemtuzumab is a therapeutic antibody that attaches to the protein CD52 on the surface of certain immunocytes, mainly T and B lymphocytes, leading to the depletion of almost all lymphocytes.

It was already known from the approval studies that a quarter of the treated patients display mostly minor side effects, called secondary autoimmune processes. In these, immunocytes turn against cells produced naturally in the body, predominantly in the thyroid gland; but the kidneys and platelets can also be affected.

The two patients described in the study received alemtuzumab because they had highly active MS, i.e. despite numerous previous treatments, they suffered from severe illness relapses with inflammation in the central nervous system. Six months after the treatment, these symptoms had worsened significantly.

Using MRI, the researchers discovered a kind of new inflammation mode: they found vast areas in the brain with numerous ring enhancing lesions. The patients had not displayed this pattern in their previous medical history.

It is currently unclear whether the observed adverse events represent increased MS activity or an independent secondary autoimmune process.

Side Effects Toned Down

In both cases, the neurologists were able to lessen the side effects, and the observed ring-shaped deposits in the brain receded. Even a year after the treatment, the patients were still in a stable condition.

Besides a blood plasma exchange, they treated both with the antibody rituximab that is directed against B lymphocytes. The researchers suspect that precisely these immunocytes were responsible for the observed side effect.

The authors propose that the measures they applied could also benefit other patients who develop similar adverse events under alemtuzumab. In MS, the body’s immune system attacks the insulating layer around the nerve fibres, the so-called myelin, and thus permanently damages the cellular protuberances.

There are now ten different classes of medications that are specially approved for MS treatment and were found to be effective in major studies. These include alemtuzumab, labled as Lemtrada.

Aiden Haghikia et al
Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy
The Lancet Neurology (2017). DOI: 10.1016/S1474-4422(16)30382-9

Image: Wellcome Trust Photographer Ben Gilbert, Wellcome Images

2 comments comments closed

  1. NOT one MS drug has ever cured MS and never ever will. Billions upon billions has been made from MS patients all exploited by the system. Even MS societys have also had billions donated. If a cure for MS was found many would no longer have a career. Wishes that someone would thoroughly scrutinize MS and lots that’s going on as one MS drug even had furniture polish added to it.

    • Hi Lynne, that one MS drug you mention, Tecfidera, is also known as Dimethyl fumarate. To quote from Wikipedia, for anyone curious: (note the second paragraph)

      “Dimethyl fumarate (DMF) is the methyl ester of fumaric acid. DMF was initially recognized as a very effective hypoxic cellradiosensitizer. Later, DMF combined with three other fumaric acid esters (FAE) was licensed in Germany as oral therapy for psoriasis (trade name Fumaderm). Other diseases, such as necrobiosis lipoidica, granuloma annulare, and sarcoidosis were also found to respond to treatment with DMF in case reports or small patient series. Phase III clinical trials found that DMF (BG-12) successfully reduced relapse rate and increased time to progression of disability in multiple sclerosis (trade name Tecfidera). DMF is thought to have immunomodulatory properties without significant immunosuppression.

      In a non-medical use, DMF was applied as a biocide in furniture or shoes to prevent growths of mold during storage or transport in a humid climate. However, due to incidences of allergic reactions after skin contact the European Union banned DMF in consumer products since 1998, and since January 2009 the import of products containing DMF was also banned.”